GDC 4379 / Roche - LARVOL DELTA

Investigation of the State of Hydration of a Non-stoichiometric Hydrate in a Low Dose Formulation Using 19F Solid-State NMR. (PubMed, J Pharm Sci) - "Owing to its high selectivity and fast acquisition times, 19F solid-state NMR was effectively utilized to directly determine the lattice water content of the active in the formulated capsule. By correlatingΔδ, the chemical shift difference between the isotropic peaks, with the relative humidity and ultimately the lattice water content, the state of hydration of GDC-4379 in the formulated capsule was experimentally determined as 0.63 moles of water/mole of anhydrate."

Journal

Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation. (PubMed, Pulm Pharmacol Ther) - "In patients with mild asthma, 14-day treatment with GDC-4379 reduced FeNO levels and peripheral biomarkers of inflammation. Treatment was well tolerated without any major safety concerns."

Biomarker • Journal • Asthma • Immunology • Inflammation • Pain • Pulmonary Disease • Respiratory Diseases

[VIRTUAL] Inhaled JAK inhibitor GDC-4379 reduces FeNO in patients with mild asthma (ERS 2021) - "GDC-0214, an inhaled small molecule JAK1 inhibitor, has reduced FeNO ~40% in patients with mild asthma. Conclusions In patients with mild asthma, 14-day treatment with GDC-4379 reduced FeNO. Treatment was well tolerated, without evidence of systemic toxicity."

Clinical • Asthma • Immunology • Otorhinolaryngology • Pain • Pulmonary Disease • Respiratory Diseases

Roche culls 2 COVID-19 drug hopefuls amid Q1 clear-out (FierceBiotech) - "Roche has cut a series of experimental lung drugs from its pipeline...Astegolimab (aka RG6149), works by stopping the binding of IL-33 to ST2. This has already flopped in asthma, like so many other IL-33s, but the Swiss giant thought it could help COVID patients with pneumonia. The trial was started last year and was slated to end in January; presumably, the results were not good, as Roche said in its first-quarter results presentation (PDF) today that it has been 'removed from phase 2'....Efmarodocokin alfa (aka RG7880), which hits IL-22 and was also 'removed from phase 2'....It did, however, have better news on a different antiviral approach, with a phase 3 test of its oral COVID-19 antiviral AT-527, partnered with Atea, slated to start in the second quarter. It also cut two phase 1 asthma prospects: RG6151 and RG6244. The former is an inhaled JAK 1 inhibitor, a class beset by safety issues and commercial struggles."

Discontinued • New P3 trial • Asthma • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases